title: [Clinical Significance of ID4 Gene Mehtylation in Demethylation-Treated MDS Cell Line and 2 MDS Patients].
abstract: OBJECTIVE
  To evaluate significance of ID4 gene mehtylation in demethylating myelodysplastic syndrome(MDS) cell Line MUTZ1 and 2 patients with MDS.
  
  
  METHODS
  The methylation-specific PCR (MS-PCR) and reverse transcription-PCR (RT-PCR) were applied to identify the methylation status and gene expression of ID4 gene in MDS cell line MUTZ1, a patient with aplastic anemia(AA) and a donor with normal bone marrow (NBM). RT-PCR was applied to detect the ID4 gene expression status in MUTZ1 cell line treated with decitabine at 3 different concentrations. Then bisulfite sequencing PCR (BSP) was applied to detect ID4 gene methylation status in 2 MDS parients treated with decitabine.
  
  
  RESULTS
  The MDS cell line MUTZ-1 displayed a complete methylation of ID4 gene promoter with little mRNA expression. Inversely, bone marrow of an AA patient and NBM showed complete unmethylation of this gene with intensity mRNA expression. With the increase of decitabine concentration, ID4 gene mRNA expression was more and more increased. After decitabine treatment, ID4 gene methylation-positive frequencies of both the 2 MDS patients were much more decreased than that of the first treatment. So, ID4 gene mRNA expression inhibited by promoter hypemethylation could be recovered by using demethylation medicine.
  
  
  CONCLUSIONS
  ID4 as a new potential anti-oncogene suggests that its methylation may become a marker for selection and assessment of therapeutic schedules in patients with MDS.
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China.|Department of Clinical Examination, Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Hui-Yuan
authors.initials: HY
authors.lastname: Kang
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Xin-Rong
authors.initials: XR
authors.lastname: Wang
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Li
authors.initials: L
authors.lastname: Gao
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Clinical Examination, Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Mian-Yang
authors.initials: MY
authors.lastname: Li
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Wang
authors.affiliation: Department of Clinical Examination, Chinese PLA's General Hospital, Beijing 100853, China.
authors.forename: Cheng-Bin
authors.initials: CB
authors.lastname: Wang
authors.affiliation: Department of Hematology; Chinese PLA's General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000741:Anemia, Aplastic; D001374:Azacitidine / Q000031:analogs & derivatives; D001853:Bone Marrow; D002460:Cell Line; D019175:DNA Methylation; D000077209:Decitabine; D015870:Gene Expression; D016147:Genes, Tumor Suppressor; D006801:Humans; D051796:Inhibitor of Differentiation Proteins; D009190:Myelodysplastic Syndromes; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic
chemical_list: C490128:ID4 protein, human; D051796:Inhibitor of Differentiation Proteins; D000077209:Decitabine; D001374:Azacitidine